The late stage biopharmaceutical firm Geron Corporation (NASDAQ:GERN) is in focus during premarket trading period this morning and has managed to clock gains of as much as 33% so far.
The stock has come into sharp focus after it emerged yesterday that the Journal of Clinical Oncology published the data from the IMbark Phase 2 clinical trial. The findings were published by the company in a paper titles “Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis.”
It is a significant development for Geron Corporation and the rally in the stock price is hence not particularly surprising. The paper that was published in the journal provided insights into the clinical benefits that had been observed during the course of the study. That included data with regards to both overall survival and also response to symptoms. At this point, it could be a good idea for investors to keep the stock in their watch lists.
Market Reaction:
As of 5:15, WECT stock soared by 32.62% to $1.86 with more than 1.92 million in the pre market session. Over the past 52-week, the stock has been trading within a range of $1.22 – $2.36.
Pivot Points
| Name | S3 | S2 | S1 | Pivot Points | R1 | R2 | R3 |
| Classic | 1.3167 | 1.3433 | 1.3767 | 1.4033 | 1.4367 | 1.4633 | 1.4967 |
| Fibonacci | 1.3433 | 1.3663 | 1.3804 | 1.4033 | 1.4263 | 1.4404 | 1.4633 |
| Camarilla | 1.3935 | 1.3990 | 1.4045 | 1.4033 | 1.4155 | 1.4210 | 1.4265 |
| Woodie | 1.3100 | 1.3400 | 1.3700 | 1.4000 | 1.4300 | 1.4600 | 1.4900 |
| DeMark | – | – | 1.3900 | 1.4033 | 1.4500 | – | – |
Moving Averages
| +/- EMA(20) | 1.43 (-1.40%) |
| +/- SMA(50) | 1.43 (-1.40%) |
| +/- SMA(200) | 1.71 (-17.54%) |
 Stock Soars: Will it Hit New High?){kind=link}